Release Details

ABIVAX Announces R&D Day at Company’s New

Collaborative Laboratory in Montpellier

• Company to Highlight Broad Product Pipeline
• R&D Day Event to be Webcasted

Paris, October 11th, 2016 – ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, announces that today it is hosting an R&D Day at the Company’s new collaborative laboratory with the French National Center for Scientific Research (CNRS) in Montpellier.

Inaugurated on September 22^nd 2016, this collaborative lab houses all of ABIVAX’s research activities on the Languedoc-Roussillon CNRS campus and is equipped with cutting-edge technological infrastructures and platforms.